Clinical Trial Update: A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial of TG103 Injection as monotherapy for Type 2 Diabetes Mellitus has completed. The study was sponsored by CSPC Baike (Shandong) Biopharmaceutical C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• TG103 Injection

Snippet

Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED